Endoscopic Sleeve Gastroplasty Versus GLP-1 Analogue for Class 1 and 2 Obesity Study

Launched by SENGKANG GENERAL HOSPITAL · Oct 4, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring two different ways to help people with obesity lose weight. Specifically, it compares a procedure called endoscopic sleeve gastroplasty (ESG) with a medication known as GLP-1 analogues. The study focuses on adults with Class 1 and Class 2 obesity, meaning those with a body mass index (BMI) between 27.5 and 39.9. The goal is to see which method leads to more weight loss over one year.

To participate in the trial, individuals must meet certain criteria. They should have a BMI in the specified range and must not have severe obesity (Class 3, which is a BMI over 40) or any health issues that would prevent them from using GLP-1 medications or undergoing the ESG procedure. Participants can expect to be monitored closely for a year to track their weight loss progress and overall health. It's important to know that this trial is not yet recruiting participants, so there will be no immediate opportunities to join at this time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with classes 1 (BMI 27.5 to 34.9) and 2 (BMI 35 to 39.9) obesity in accordance with the World Health Organisation recommendations but modified to the interventional thresholds recommended for Asian populations
• Exclusion Criteria:
• • Patients with class 3 obesity and above (BMI \> 40.0)
• • Patients with contraindications to GLP-1 analogues
• • Patients with contraindications to endoscopic sleeve gastroplasty
• • Patients with previous bariatric or upper gastrointestinal surgery